Compare Amgen, Inc. (AMGN) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ON Holding AG — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while ON Holding AG trades at $31.05 (market cap $10.33B). The key difference: Amgen, Inc. is far larger — about 21.7× ON Holding AG's market cap, and Amgen, Inc. pays a 2.43% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| AMGN | ONON | |
|---|---|---|
Market Cap | $224.14B | $10.33B |
Sector | Health | Technology |
52-Week High | $417.20 | $50.63 |
52-Week Low | $271.18 | $30.91 |
Enterprise Value | $267.45B | $9.47B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
ONON stock is trading at $31.01, down 20.04% after Q2 2026 results showed a revenue miss and lowered full-year growth guidance. The technical picture is bearish with support near $29, while fundamentals reveal strong profitability margins and earnings beats. Analyst sentiment remains largely positive despite the sell-off, with a consensus price target of $52.86.
The outlook is mixed: robust DTC growth and margin expansion offer upside, but wholesale softness and guidance cuts pose near-term risks. Investors face volatility from consumer spending concerns and competitive pressures, though long-term brand momentum supports a growth-at-a-reasonable-price thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
